Delhi Pharma Company to Get IP for Alzheimer’s disease (AS)
Chethan Kumar, 13 May 2022
remove_red_eye 536 Views
#Multispeciality
Coronavirus Live Count Map India
remove_red_eye 536 Views
COVID-19 Vaccine Updates
#Multispeciality
Scientists at the Jawaharlal Nehru Centre for Advanced Scientific Research (JNCASR) developed a drug molecule for Alzheimer’s treatment more than a year ago. A Delhi-based pharma, Hamsa Biopharma has obtained the intellectual property rights of the path-breaking drug molecule. The company will design and implement drug post-marketing trials along with its parent company in the US, IGC pharma.The drug molecule, TGR63 works on the pathways that render neurons i.e., brain cells dysfunctional ...
Create Account
Login Now
To read the complete article ,
create a free account.
Sign Up
to instantly read 30000+ free Articles & 1000+ Case Studies
Already registered?
terrific breakthrough in Pharma....a big boon not just for patients but also for care givers